Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes

Cirena licenses breakthrough RNA synthesis technology from CU Boulder

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications

KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units

The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations